Blog
The Parathyroid Paradox: Why the Same Peptide Can Weaken or Build Bone Depending on How It Is Given
In the 1920s, researchers found that excess parathyroid hormone makes bones lose calcium. In the 1980s, a Canadian team found that the same hormone, injected in the right way, makes bone grow. It sounds like a contradiction. It is actually one of the clearest demonstrations of how peptide timing works.
Key takeaways
- Parathyroid hormone, PTH, is a peptide of 84 amino acids; the first 34 carry most of the activity.
- Persistently high PTH, as in overactive parathyroid glands, causes bone loss.
- In 1982 Tam, Heersche, Murray and colleagues showed that daily injections of PTH increased bone formation in rats.
- Brief rises favor bone-building cells; constant exposure favors bone-removing ones.
- The fragment PTH(1-34), teriparatide, was approved in the United States in 2002.
The old story
PTH was identified in the 1920s, in part through the work of James Collip, whose purification skills are described in our Collip post. It raises blood calcium by acting on bone and kidney. In disease models and in patients with overactive glands, constant high PTH pulled calcium out of bone. Naturally, no one expected PTH to help build it.
The surprise
In 1982, a team with members in Toronto and London gave rats PTH in two ways. When they infused it continuously, bone was resorbed. When they gave it as a single daily injection, the animals laid down more new bone. Both treatments contained the same peptide in the same total amount. Only the timing differed.
Why timing flips the effect
PTH acts on bone-forming cells, called osteoblasts, which in turn signal bone-removing cells. A brief pulse activates the bone-forming program first, and the signal fades before the resorbing program catches up. Constant exposure keeps both going, and the resorbing side wins. The idea is conceptually similar to the receptor effects in the Knobil experiment and our desensitization post.
Why a fragment
The first 34 amino acids of PTH contain the receptor-binding and activating parts, so PTH(1-34) mimics the hormone and can be made by chemical synthesis, which is much easier than making the full 84 amino acids, as shown in our length and yield post. It was developed as the drug teriparatide and approved in 2002.
What researchers take from it
- The same peptide can have opposite effects depending on exposure pattern.
- Dose alone does not describe an experiment; frequency and duration matter.
- Half-life and delivery design the pattern, as in half-life engineering.
- Fragments can carry the full activity, a theme seen in the KPV fragment.
The bottom line
The PTH paradox is a favorite teaching example because it fits on a single line: same peptide, same amount, different timing, opposite result. Keep that in mind whenever you read a peptide study, and see how we document each lot on our lab reports page.
Related reading
- The Knobil experiment
- The chemist who made insulin usable
- Receptor desensitization
- Browse the full Research Library
Explore Lucid Aminos
- Shop all research compounds
- Read the lab reports (COA)
- Monthly Research Panel
- Frequently asked questions
- Partner program
- About Lucid Aminos
- Contact us
For laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any condition. This article is educational and is not medical advice.